Dr. Levy On The Treatment Of T790M-Mutant Lung Cancer

Dr. Levy on the Treatment of T790M-Mutant Lung Cancer

Dr. Levy on the Role of Chemotherapy in the Treatment of Lung Cancer

Targeted Oncology

Dr. Levy on EGFR TKIs in Lung Cancer

Osimertinib in T790M-Mutant Lung Cancer

2020 CBPD LEVY - CASE 1 - Timing and Treatment for 48 YO Male with EGFR NSCLC High PDL1

GRACE - Global Resource for Advancing Cancer Education

Dr. Levy on Treatments for Oncogenic-Driven NSCLC

Dr. Levy on First-Line Treatment for Nondriver NSCLC

Dr. Lynch Discusses Treating Patients With T790M-Mutant NSCLC

Targeted Oncology

Dr. Levy Discusses the FLAURA Study in Lung Cancer

How to Understand EGFR T790M Mutations | Dana-Farber Cancer Institute

Dana-Farber Cancer Institute

Lung Cancer Video Library 2020 - LEVY - Immunotherapy in Patients with Driver Mutations

GRACE - Global Resource for Advancing Cancer Education

Osimertinib in Advanced EGFR T790M-Mutant NSCLC

Dr. Levy on Positive and Negative Biomarkers for Immunotherapy in Lung Cancer

Dr. Levy on Biomarkers of Response to Immunotherapy

Osimertinib for the T790M Resistance Mutation

Repeat biopsy in lung cancer patients with EGFR mutation

Options for EGFR Mutation-Positive Patients with T790M Mutation-Negative Acquired Resistance

GRACE - Global Resource for Advancing Cancer Education

Osimertinib in Advanced EGFR T790M-Mutant NSCLC

Benjamin Levy on Advances in Diagnosing Lung Cancer

Dr. Husain on the Future of Monitoring T790M in Lung Cancer